Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
26 07 2019
Historique:
entrez: 13 8 2019
pubmed: 14 8 2019
medline: 18 6 2020
Statut: epublish

Résumé

The influenza virus remains a significant cause of mortality worldwide due to the limited effectiveness of currently available vaccines. A key challenge to the development of universal influenza vaccines is high antigenic diversity resulting from antigenic drift. Overcoming this challenge requires novel research tools to measure the breadth of serum antibodies directed against many virus strains across different antigenic subtypes. Here, we present a protocol for analyzing the breadth of serum antibodies against diverse influenza virus strains using a protein microarray of influenza antigens. This influenza antigen microarray is constructed by printing purified hemagglutinin and neuraminidase antigens onto a nitrocellulose-coated membrane using a microarray printer. Human sera are incubated on the microarray to bind antibodies against the influenza antigens. Quantum-dot-conjugated secondary antibodies are used to simultaneously detect IgG and IgA antibodies binding to each antigen on the microarray. Quantitative antibody binding is measured as fluorescence intensity using a portable imager. Representative results are shown to demonstrate assay reproducibility in measuring subtype-specific and cross-reactive influenza antibodies in human sera. Compared to traditional methods such as ELISA, the influenza antigen microarray provides a high throughput multiplexed approach capable of testing hundreds of sera for multiple antibody isotypes against hundreds of antigens in a short time frame, and thus has applications in sero-surveillance and vaccine development. A limitation is the inability to distinguish binding antibodies from neutralizing antibodies.

Identifiants

pubmed: 31403629
doi: 10.3791/59973
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Antigens, Viral 0
Hemagglutinin Glycoproteins, Influenza Virus 0
Influenza Vaccines 0
Viral Proteins 0
NA protein, influenza A virus EC 3.2.1.18
Neuraminidase EC 3.2.1.18

Types de publication

Evaluation Study Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR001416
Pays : United States

Auteurs

Saahir Khan (S)

Division of Infectious Diseases, Department of Medicine, University of California Irvine Health.

Aarti Jain (A)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Omid Taghavian (O)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Rie Nakajima (R)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Algis Jasinskas (A)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Medalyn Supnet (M)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Jiin Felgner (J)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Jenny Davies (J)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Rafael Ramiro de Assis (RR)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Sharon Jan (S)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Joshua Obiero (J)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Erwin Strahsburger (E)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Egest J Pone (EJ)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Li Liang (L)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

D Huw Davies (DH)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine.

Philip L Felgner (PL)

Vaccine Research and Development Center, Department of Physiology, University of California Irvine; pfelgner@uci.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH